Patients with type 2 diabetes treated with canagliflozine, marketed with the name of Invokana by Janssen, maintain a better therapeutic adhesion than those treated with DPP-4 inhibitors, a common class of antidiabetics, including sitegogtin.
This has been shown by four studies that have compared both therapies and that have been presented at the last annual scientific meeting of the American Diabetes Association (ADA), recently held in New Orleans, United States.
Likewise, the data suggest that Canaglifozin is associated with greater blood glucose control and blood pressure figures, which are key aspects in the treatment of diabetes.During this meeting there have been a total of 18 abstracts with canagliflozine data.
"These data facilitate identifying what are the most appropriate therapeutic options in each case"
As the vice president of the Janssen Medical Department, Paul Burton, "Account that up to half of the diabetics do not meet the therapeutic objectives.
A1C or hemoglobin A1C is a measure of the present amount of blood glucose of the last two-three months.The ADA recommends for adult patients with type 2 diabetes Maintain these levels at 7% or below this figure.
Of the four comparative studies, in one of them it was observed that the patients who had received the type 2 sodium-glucose transporter inhibitor (ISGLT2), canagliflozine, remained longer with the therapy after nine months of treatment, in front of the treaties with treaties withDPP-4 inhibitors, Dapagliflozina, or an GLP-1 receiver agonist.
Canagliflozine
Since last year this medicine is approved in Spain to improve glucose levels in adult patients with type 2 diabetes mellitus, accompanied by diet and physical exercise.It is administered orally once a day and belongs to a new therapeutic class, type 2 sodium-glucose transporter (SGLT2).
Phase III studies data that support their authorization showed that their use achieves, in addition to favoring the elimination of glucose through urine, reducing weight and blood pressure figures.Canagliflozine is indicated in 18 -year -old adults or older with type 2 diabetes mellitus to improve glycemic control in monotherapy or as a complementary and administered treatment with other antihyperglycemic.
Source: consalud.es
